Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11426404 Dosing of

Patent 11426404 was granted and assigned to Amgen on August, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Haby Henary0

James Russell Lipford0

Victor J. Cee0

Date of Patent

August 30, 2022

0

Patent Application Number

159306060

Date Filed

May 13, 2020

0

Patent Citations

US Patent 10532042 KRAS G12C inhibitors and methods of using the same

US Patent 10640504 Inhibitors of KRAS G12C and methods of using the same

US Patent 10988485 KRAS G12C inhibitors and methods of using the same

0

US Patent 11045484 KRAS G12C inhibitors and methods of using the same

US Patent 11053226 KRAS G12C inhibitors and methods of using the same

US Patent 11090304 KRAS G12C inhibitors and methods of using the same

US Patent 11236091 Solid state forms

0

US Patent 11096939 KRAS G12C inhibitors and methods of using the same

...

Patent Citations Received

US Patent 12083121 Substituted piperazines as KRAS G12C inhibitors

0

US Patent 11905281 KRAS G12C inhibitors and methods of using the same

0

US Patent 11918584 Combination therapy including a KRAS

0

US Patent 11993597 Inhibitors of KRAS G12C and methods of using the same

0

US Patent 11766436 KRAS G12C inhibitors and methods of using the same

Patent Primary Examiner

0

CPC Code

0

Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11426404 Dosing of

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool